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doi:10.1016/j.kjms.2010.05.002Abstract Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant inher-
ited disease predisposing to the development of colorectal cancers and several other malignan-
cies (endometrium, ovaries, stomach, small bowel, hepatobiliary, and urinary tract). HNPCC is
caused by germline mutations in any of the mismatch repair genes. Mutations inMLH1 andMSH2
account for almost 90% of all identified ones. Here, we report a Taiwanese family with HNPCC
and mutation analysis revealed a novel nonsense mutation (S611X) in MSH2 gene.
摘要 遺傳性非瘜肉性大腸直腸癌是一體染色體顯性遺傳疾病，病人及家族成員除大腸直腸癌
外，常合併子宮內膜癌、卵巢癌、胃癌、小腸癌、肝膽囊系統及泌尿道系統癌。DNA 錯誤配對修
補基因的突變是造成遺傳性非瘜肉性大腸直腸癌的原因，其中90%患者可找到MSH2或MLH1基因
的突變。本篇報告一台灣遺傳性非瘜肉性大腸直腸癌家族之MSH2新基因突變點(S611X)。
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC; Online
Mendelian Inheritance in Man 120435) is an autosomalColon and Rectal Surgery,
eng-Kung University Medical
ad, Tainan, Taiwan.
du.tw (J.-C. Lee).
vier Taiwan LLC. All rights reserdominant inherited disease predisposing to the development
of colorectal cancers (Lynch syndrome 1) and several other
malignancies, such as cancer of endometrium, ovaries,
stomach, small bowel, hepatobiliary, and urinary tract
(Lynch syndrome 2) [1,2].
Patients affected by HNPCC can be identified on the
basis of clinical criteria, such as age at onset of
neoplasms and characteristics of the family history.
Amsterdam criteria were the first guideline drawn toved.
Figure 1. Pedigree of the hereditary nonpolyposis colorectal
cancer (HNPCC) family. Affected females are indicated by C,
affected males by -, and proband by ➚.
MSH2 mutation in HNPCC 69identify families prone to develop HNPCC [3]. Because
Amsterdam criteria were judged too stringent and with
inadequate sensitivity, Bethesda guidelines were advised
aiming to identify patients who should undergo genetic
testing [4,5]. More recently Bethesda criteria were
revised; they are now considered the most accurate
clinical criteria for the identification of patients at risk
for HNPCC [6,7].
HNPCC is caused by germline mutations in any of the
mismatch repair (MMR) genes: MLH1, MSH2, MSH6, MSH3,
and PMS2 genes. Mutations in MLH1 and MSH2 account for
almost 90% of all identified ones. Failure of the MMR
system results in the inability to repair errors that can
occur during DNA replication. One of the consequences of
this condition is the so-called microsatellite instability,
which is the hallmark of HNPCC tumors. Assays for
microsatellite instability, together with family history, can
be used to determine whether a patient could be a carrier
of a MMR mutation and if he is worth undergoing genetic
tests [8].
In this report, we describe the genetic analysis of the
MSH2 and MLH1 genes in a Taiwanese family with HNPCC.Table 1 Polymerase chain reaction primers used for the amplifi
Exon Forward (5’/3’) Backwar
1 GAGCTCTACTAAGGATGCGC GAATCC
2 CATGACTTGTTCCTCCTTGC CTCAGC
3 CACCATTGCACTCTAGCCTG CTTTCC
4 CAGTGAGCCAAGATCGTGTC CATTGT
5 CTTGGTTTGGATTGGGAAGG CAACTA
6 CACCACTGCACTCCAGTCTG CTCCTC
7 CAAAGTGCTGGGATTACAGG CTGAGA
8 GTAACTTTGGAGACCTGCTG CTCTTT
9 CATCATCAGCACTGTAACTG GTATCC
10 GTGCTCTGCAGCCTTGGATG CAGAGC
11 CAGGAATTGTGCCATTGCGC GTACGT
12 GTTGAGTTTTAGGTGGGTTC CTCTGA
13 GCAGTAACTCTGTCCACATC GAAGTG
14 CTGGCCCTTGCCCATTTTTC GTTGCA
15 CTGTGTGCCAAGTCATAATC GAGGGC
16 GCAACATAGTGAGACCCTCG GTCACA
a The amplification conditions were 94C for 5 min followed by 40 cy
for 45 sec, and extension at 72C for 10 min.
ATZ annealing temperature.Case presentation
Family characteristics
The proband was a 50-year-old female (II-8), whose personal
and family history fulfilled the Amsterdam II criteria for
HNPCC. She was diagnosed with adenocarcinomas of the
ascending colon cancerwithmultiple polypswhen shewas 49
and underwent subtotal colectomy (Stage IIB, T4N0M0,
Dukes’ stage B2). Detailed patient family history was
collected: pedigree was drawn (Fig. 1). Patient’s family
showed a typical HNPCC pedigree (Lynch 1 syndrome).
Patient’s father (I-1) had a colon cancer and died at the age
of 66. Patient’s sisters developed colorectal cancers when
they were 30 (II-1) and 45 (II-7), respectively. Her brothers
developed colorectal cancers when they were 50 (II-2),
43 (II-4), and 40 (II-6), respectively.
Polymerase chain reaction and automated DNA
sequencing
Genomic DNA was extracted from peripheral blood of the
proband and families after obtaining informed consent
(QIAamp Midi kit; Qiagen, Valencia, CA, USA). DNA samples
were then subjected to mutation screening by amplification
of segments of the MSH2 (Table 1) and the MLH1 gene with
primers synthesized on the basis of intronic sequences from
Genbank [14].
For polymerase chain reaction amplification, approxi-
mately 200 ng of genomic DNA, 12.8 pmol of each primer,
10 mmol deoxyribonucleotide triphosphate, and 1.25 U of
Taq (Qiagen, Chatsworth, NJ, USA) were used in a total
volume of 50 mL. The amplification conditions were 94C for
five minutes followed by 40 cycles of 94C for 45 seconds,
annealing temperature for 45 seconds and 72C for 45cation of the MSH2 gene from genomic DNAa
d (5’/3’) Product size AT
GCACAAGCACCAAC 630 55C
CTCCCAAAATACTG 556 60C
TAGGCCTGGAATCT 493 55C
ACTCCAGCCTGGGC 661 55C
CTTGGGAGGTGGAG 572 55C
TTCCCCAACAAACC 1,048 60C
TTGTGCCACTGCAC 543 55C
CCGTTTCCAGTGAC 578 55C
TGTTACCAGTGGAC 575 55C
GAGACTCCATCTCC 625 60C
TGTAGGCCCTAGTG 600 55C
ACCCATGGAAGAAG 683 50C
TGAACAGTCCAAGC 670 50C
GTGAGCCGAGATCG 721 60C
AGGAATTATGAATC 776 50C
CTGCGAAGAACTAC 639 55C
cles of 94C for 45 sec, annealing temperature for 45 sec and 72C
Figure 2. Automated DNA sequencing of the MSH2 gene. (A)
Sequence from the proband revealed a C to G transition
(1832C>G), which resulted in premature termination of codon
(S611X); (B) Sequence from normal control; (C) Sequence from
proband with reverse primer.
70 W.-C. Chen et al.seconds, and extension at 72C for 10 minutes. Polymerase
chain reaction products were purified by QIAquick columns
(Qiagen, Chatsworth, NJ, USA) and sequenced with both
forward and backward primers (377 ABI Advanced
Biotechnologies, Columbia, MD, USA).
Automated DNA sequencing of the MSH2 gene revealed
a nonsense mutation (1832C>G, S611X) (Fig. 2A). This
mutation was confirmed with backward primer (Fig. 2C). No
mutation was detected in the MLH1 gene of this patient.
Discussion
HNPCC affects roughly 1 in 5,000 people, accounting for
3%e10% of all colorectal cancer cases. In HNPCC, colorectal
cancer occurs earlier than in sporadic cases, on average,
between the ages of 40 and 50 [9].
HNPCC may be totally without symptoms, especially if
the patient is being investigated at young age because of
a positive family history of the disease. However, it can
present with rectal bleeding, stomach pain, or symptoms
related to the variety of cancers associated with it.
Although the name suggests otherwise, HNPCC does cause
the formation of polyps (less than 100)dbut still far fewer
than seen in familial adenomatous polyposis. In HNPCC, the
polyps themselves are not cancerous, but they can rapidly
degenerate to cancer within 2e3 yearsdquicker than the
8e10 years taken in sporadic cases [10].The lifetime risk of HNPCC patients developing colo-
rectal cancer is estimated to be about 70%e80% and female
patients have a significantly higher risk of endometrial and
ovarian cancer (39% and 9%, respectively, by the age of 70).
HNPCC also increases the susceptibility of patients to other
cancers, including the stomach, intestine, hepatobiliary
system, urinary system, skin, and brain.
Nowadays, HNPCC is suspected by doctors following
a thorough history (especially family history) and exami-
nation. The genetic basis of HNPCC has been attributed to
the genetic and epigenetic changes of MMR genes, such as
MSH2, MLH1, and others [11]. If indicated, the patient may
have a gene test or colonoscopy to confirm the diagnosis.
MLH1 and MSH2 mutations are spread in all regions of these
genes, without hot spots. Mutations detection strategies
must therefore cover the entirety of these genes [12,13].
Here, we report a novel MSH2 germline nonsense mutation
caused by the substitution of cysteine with a guanine
(1832C>G) in Exon 12 of MSH2 gene. This alteration
produces a serine to stop codon in position 611 of the
primary sequence (S611X). Nonsense, splice site and trun-
cating mutations are considered pathogenetic. The family
members with positive cancer history (II-1, II-2, II-4, II-6,
and II-7) having the same point mutation confirm the
importance of this nonsense mutation. The genetic confir-
mation of mutation in HNPCC provides crucial information
for genetic counseling. Patients from affected families can
undergo genetic testing. To help prevent colorectal cancer,
those with a proven MMR mutation are recommended to
have a colonoscopy every two years, from the age of 25, or
from an age five years younger than the earliest colorectal
cancer case seen in the family.
Acknowledgments
The authors thank the family members for their participa-
tion in the study. This study was supported by research
grant NCKUH 96-075 from the National Cheng Kung
University Hospital, Taiwan, Republic of China.
References
[1] de la Chapelle A. Genetic predisposition to colorectal cancer.
Nat Rev Cancer 2004;4:769e80.
[2] Merg A, Lynch HT, Lynch JF, Howe JR. Hereditary colorectal
cancer-part II. Curr Probl Surg 2005;42:267e333.
[3] Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International
Collaborative Group on Hereditary Non-Polyposis Colorectal
Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424e5.
[4] Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE,
Jass JR, Khan PM, et al. A National Cancer Institute Workshop
on hereditary nonpolyposis colorectal cancer syndrome:
meeting highlights and Bethesda guidelines. J Natl Cancer Inst
1997;89:1758e62.
[5] Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines
for hereditary non-polyposis colorectal cancer. Nat Rev
Cancer 2004;4:153e8.
[6] Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A,
Ru¨schoff J, et al. Revised Bethesda guidelines for hereditary
non-polyposis colorectal cancer (Lynch syndrome) and
microsatellite instability. J Natl Cancer Inst 2004;96:261e8.
[7] Pinol V, Castells A, Andreu M, Castellvı´-Bel S, Alenda C, Llor X,
et al. Accuracy of revised Bethesda guidelines, microsatellite
MSH2 mutation in HNPCC 71instability and immunohistochemistry for the identification of
patients with hereditary non-polyposis colorectal cancer. JAMA
2005;293:1986e94.
[8] Boland CR, Thibodeau SN, Hamilton SR, Sidransky D,
Eshleman JR, Burt RW, et al. A National Cancer Institute
Workshop on microsatellite instability for cancer detection
and familial predisposition: development on international
criteria for the determination of microsatellite instability in
colorectal cancer. Cancer Res 1998;58:5248e57.
[9] Parc Y, Boisson C, Thomas G, Olschwang S. Cancer risk in 348
FrenchMSH2orMLH1genecarriers. JMedGenet 2003;40:208e13.
[10] Thorson AG, Faria J. Familial adenomatous polyposis, hereditary
nonpolyposis colon cancer, and familial risk: what are the impli-
cations for the surgeon? Surg Oncol Clin N Am 2000;9:683e701.[11] Peltomaki P, de la Chapelle A. Mutations predisposing to
hereditary nonpolyposis colorectal cancer. Adv Cancer Res
1997;71:93e119.
[12] Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT,
Watson P, et al. Analysis of mismatch repair genes in heredi-
tary non-polyposis colorectal cancer patients. Nat Med 1996;
2:169e74.
[13] Peltomaki P, Vasen HF. Mutations predisposing to hereditary
nonpolyposis colorectal cancer: database and results of
a collaborative study. The International Collaborative Group
on hereditary non-polyposis colorectal cancer. Gastroenter-
ology 1997;113:1146e58.
[14] (MSH2: http://www.ncbi.nlm.nih.gov/nuccore/NG_007110.1;
MLH1: http://www.ncbi.nlm.nih.gov/nuccore/NG_007109.1).
